Rana R. McKay, MD, presented “Overall Survival with Sipuleucel-T in Patients Treated for Advanced Prostate Cancer” for the Grand Rounds in Urology audience in December 2020.
How to cite: McKay, Rana R. “Overall Survival with Sipuleucel-T in Patients Treated for Advanced Prostate Cancer” December 2020. Accessed Jan 2021. https://grandroundsinurology.com/overall-survival-with-sipuleucel-t-in-patients-treated-for-advanced-prostate-cancer/
Rana R. McKay, MD, Associate Professor of Medicine at the University of California, San Diego, and Co-Leader of the Genitourinary Oncology Disease Team at the Moores Cancer Center, discusses the results of a real-world analysis examining survival outcomes in Medicare beneficiaries with metastatic castrate-resistant prostate cancer (mCRPC) who were treated with sipuleucel-T and more recently-approved novel hormonal agents in a real-world treatment setting. Dr. McKay explains that findings show that, for the population studied, use of sipuleucel-T and oral agent results in a statistically significant improvement in overall survival and reduction in mortality compared to patients who never received sipuleucel-T, regardless of when it was given. Following her presentation, E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology, conducts a Q&A session with Dr. McKay in which they discuss the increasing acceptance of sipuleucel-T among medical oncologists, how complementary MOAs may improve patient outcomes, and the future of sipuleucel-T, among other clinical topics.